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INTRODUCTION 
 
Over the past decades, major advances have been 
made in the understanding of the role of amyloid and 
cerebrovascular pathology in the onset and 
progression of Alzheimer’s disease (AD) [1]. 
However, the underlying number of pathological 
changes and the subsequent final trigger leading to 
clinical disease manifestation, remain largely unclear. 
AD has a strong genetic component with a 
heritability of 60-80%, with additional AD-
susceptibility genes that are still being identified [2, 
3]. These findings suggest that an individual’s 
genetic architecture is key in determining if and when 
disease emerges [2-4]. Notwithstanding the 
importance of environmental and lifestyle factors, it 
remains difficult to quantify to what extent this 
genetic predisposition is deterministic for AD onset. 
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ABSTRACT 
 
In cancer research, multistage models are used to assess the multistep process that leads to the onset of 
cancer. In view of biological and clinical similarities between cancer and dementia, we used these models to 
study Alzheimer’s disease (AD). From the population-based Rotterdam Study, we included 9,362 non-demented 
participants, of whom 1,124 developed AD during up to 26 years of follow-up. Under a multistage model, we 
regressed the logarithm of AD incidence rate against the logarithm of five-year age categories. The slope in this 
model reflects the number of steps (n–1) required for disease onset before the final step leading to disease 
manifestation. A linear relationship between log incidence rate and log age was observed, with a slope of 12.82 
(95% confidence interval: 9.01-16.62), equivalent to 14 steps. We observed fewer steps for those at high 
genetically determined risk: 12 steps for APOE-ε4 carriers, and 10 steps for those at highest genetic risk based 
on APOE and a genetic risk score. The pathogenesis of AD complies with a multistage disease-model, requiring 
14 steps before disease manifestation. Genetically predisposed individuals require fewer steps indicating that 
they already inherited multiple of these steps. Unravelling these steps in AD pathogenesis could benefit the 
development of intervention strategies. 
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Originated in cancer research, multistage models have 
been used to gain more insight in the number of steps 
before disease manifestation. These models are able to 
estimate the number of steps (‘mutations’) required for 
a healthy cell to become malignant [5]. After 
undergoing several of these rate-limiting steps, the last 
mutation will ultimately lead to clinical manifestation of 
the disease. These models have yielded consistent 
findings across a variety of cancers, supporting the 
notion that the occurrence of cancer is the end result of 
seven, successful mutations [5].  
 
Cancer and neurodegenerative disease, including AD as 
its most common form, may be seen as two opposite 
ends in cell proliferation. Yet they share biological and 
clinical characteristics, including dysregulations in key 
DNA repair and inflammation processes, an increasing 
incidence with advancing age, and rapid disease 
progression after diagnosis [6, 7]. Moreover, they share 
a complex inheritance pattern with genetic pleiotropy 
[8]. For instance, a recent GWAS found a positive 
genetic correlation between AD and cancer genes, 
further supporting the genetic overlap between these 
two diseases [8].  
 
Given the commonalities between neurodegenerative 
diseases and cancer, the multistage model has recently 
been successfully applied to model the incidence rate of 
amyotrophic lateral sclerosis, a rare neurodegenerative 
disease, as a six-step process [9]. So far, this multistage 
modelling has not been used for AD. We therefore 
applied a multistage model within a large, population-
based study to test the hypothesis that AD is a 
multistage process. We determined the number of steps 
required for disease onset and hypothesized that if AD 
complies with a multistage process, the number of steps 
will be smaller in genetically predisposed individuals as 
these individuals may already inherited one of these key 
steps.  
 
RESULTS 
 
During a follow-up of up to 26.1 years, 1,124 out of 
9,362 participants were diagnosed with AD, (median 
follow-up 10.3 years [interquartile range 10.1 years].). 
Table 1 shows the baseline characteristics of the study 
population. In this sample, 58.2% of the participants 
were women. Of the included participants, 2,624 were 
APOE ε4 carriers (28.0%). 
 
Multistep model 
 
The adjusted R-squared for the relation between log AD 
incidence rate and log age was 0.93, indicating a linear 
correlation, which is in line with the multistage model. 
The estimate of the slope (number of steps minus 1) for  
Table 1. Baseline characteristics of total study 
population. 
Characteristic Study population (N=9,362) 
Age, median (IQR), y 65.0 (12.6) 
Women 5,453 (58.2) 
APOE ε4 carrier 2,624 (28.0) 
Weighted genetic risk score  
  First tertile  3,146 (33.6) 
  Second tertile  3,120 (33.3) 
  Third tertile  3,096 (33.1) 
Educational level  
  Primary 1,689 (18.3) 
  Lower 3,941 (42.6) 
  Further 2,512 (27.2) 
  Higher 1,101 (11.9) 
Body mass index, mean (SD), kg/m2 26.8 (3.9) 
Systolic blood pressure, mmHg,  
mean (SD) 140 (22) 
Diastolic blood pressure, mmHg,  
mean (SD) 76 (12) 
Total cholesterol, mmol/L,  
mean (SD) 6.3 (1.2) 
Diabetes mellitus 1,026 (11.0) 
Smoking status  
  Never 3,021 (32.7) 
  Former 4,276 (46.3) 
  Current 1,938 (21.0) 
No alcohol use 1,416 (17.3) 
Abbreviations: APOE, apolipoprotein E; IQR, 
interquartile range; SD, standard deviation. Data are 
presented as number (percentage) of participants unless 
otherwise indicated. Values are shown without 
imputation and therefore not always add up to 100%. 
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Table 2. Overview of estimates for slopes across groups with different genetic risks. 
Study population n/N n-1  (95%CI) 
R-squared*  
Total study population 1,124/9,362 12.82 (9.01-16.62) 0.925 
     
APOE ε4 Carrier 481/2,624 10.56 (5.96-15.17) 0.849 
 Homozygote 70/213 8.92 (5.74-12.11) 0.923 
 Heterozygote 411/2,411 14.93 (8.11-21.75) 0.878 
 Non-carrier 643/6,738 15.02 (11.28-18.76) 0.946 
     
Weighted genetic risk score 
tertile First 296/3,146 15.04 (9.41-20.68) 0.885 
 Second 376/3,120 12.8 (9.94-15.65) 0.956 
 Third 452/3,096 11.72 (7.37-16.08) 0.886 
     
Weighted genetic risk score 
first tertile APOE ε4 carrier 124/843 8.47 (1.91-15.04) 0.886 
 APOE ε4 non-carrier 172/2,303 15.3 (11.77-18.82) 0.954 
Weighted genetic risk score 
second tertile APOE ε4 carrier 161/930 10.31 (6.83-13.79) 0.905 
 APOE ε4 non-carrier 215/2,190 15.54 (12.02-19.05) 0.955 
Weighted genetic risk score 
third tertile APOE ε4 carrier 196/851 8.93 (3.51-14.36) 0.738 
 APOE ε4 non-carrier 256/2,245 14.39 (9.81-18.97) 0.915 
Abbreviations: APOE, apolipoprotein E; n, number of incident Alzheimer’s disease events; N, total number of 
participants; n-1, estimate for slope (i.e. number of steps minus 1). 
*Obtained from linear regression model log(Alzheimer’s disease incidencei) = β0 + β1*log(agei)  
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AD was 12.8 (95% confidence interval (CI): 9.0-16.6), 
indicating that 14 steps are needed for the development 
of AD (Table 2, Figure 1).  
 
Considering genetic risk 
 
When considering only the APOE-related risk of 
developing AD, we found that APOE ε4 genotype non-
carriers needed more steps to develop AD compared to 
APOE ε4 carriers (16 steps for non-carriers, 12 for 
carriers). In an exploratory analysis, we also examined 
the number of steps among participants homo- or 
heterozygous for APOE ε4 separately. Participants 
homozygous for the APOE ε4 allele required 10 steps, 
while participants heterozygous for APOE with ε3 and 
ε4 or ε2 and ε4 required 16 steps to develop AD. 
Similarly, we found for participants in the low-risk 
tertile of the genetic risk score that more steps were 
required to develop AD compared to those in the high-
risk tertile (16 steps versus 13 steps). When stratifying 
on both APOE ε4 carrier ship and the genetic risk score, 
we found that for every increase in tertile of the genetic 
risk score, APOE ε4 carriers needed less steps to 
develop AD compared to the APOE ε4 non-carriers. 
This translated into ten steps for APOE ε4 carriers in the 
high-risk tertile, compared to 16 steps for non-carriers 
for APOE in the low-risk tertile (Table 2). 
DISCUSSION 
 
In this population-based study using long-term follow-up 
of AD, we found evidence that the development of AD 
follows a multistage process with 14 steps. This indicates 
that 14 steps are required for the clinical occurrence of 
AD in the general population. The number of steps was 
modified by the level of genetic predisposition, 
translating into six less steps for those individuals at 
highest genetic risk for AD, compared to those at the 
lowest genetic risk. 
 
The multistage models have been extensively used in 
cancer research to provide more insight in their 
underlying pathogenesis [10-14]. Several studies showed 
that seven steps were required to develop cancer, which 
may reflect somatic mutations, genomic rearrangements, 
or changes in tissue interactions and environment. 
Neurodegenerative diseases show several similarities with 
cancer such as dysregulation of DNA repair mechanisms. 
Yet, the multistage model has only been applied to 
amyotrophic lateral sclerosis which appears to follow a 
multistage process with six rate-limiting steps. In this 
study, we show that AD also can also be modelled as a 
multistage condition consisting of 14 steps, stressing the 
genetic complexity and the variety of potential biological 
pathways involved in the development of this disease.  
 
 
Figure 1. Plotted log incidence rate of Alzheimer’s disease (y-axis) against log age (x-axis). The dashed line shows the most 
optimal linear correlation. 
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We found that the number of steps for AD differed 
between individuals with different degrees of genetic 
predisposition. APOE ε4 carriers require a smaller 
number of steps to develop AD compared to APOE ε4 
non-carriers. Moreover, these effects became even more 
pronounced when additionally considering 23 AD-
associated genetic variants. Compared to those at 
highest genetic risk (i.e. APOE ε4 carrier and within the 
third tertile of the weighted genetic score), individuals 
at lowest genetic risk (i.e. APOE ε4 non-carrier and 
within the first tertile of weighted genetic score) needed 
six more rate-limiting steps to develop AD. These 
findings are in line with previous observations in cancer 
research showing different thresholds before disease 
becomes clinically apparent between inherited and 
sporadic cancer events. For instance, individuals with 
familial adenomatous polyposis are at increased risk of 
colon cancer due to one mutated copy of the APC gene. 
It has been shown that these individuals need one step 
fewer in the overall pathological process to develop 
clinical colon cancer than individuals without this 
mutated gene [10]. Furthermore, children with inherited 
retinoblastoma required only one hit to develop this 
disease, whilst sporadic retinoblastoma cases became 
clinically apparent after two hits [15]. Our findings may 
suggest that individuals with genetic predisposition 
begin several stages further down the chain of the 
required pathological threshold before AD becomes 
clinically apparent. 
 
Although our findings suggest that 14 steps are needed 
for AD to emerge clinically, the underlying biological 
pathways and changes reflected by these steps still need 
to be identified. To date, eight different biological 
pathways involved in the pathogenesis of AD have been 
identified using genetic variants in AD [16]. The APOE 
ε4 allele is the most significant genetic risk factor due to 
its high prevalence and strong relation to AD. It is 
involved in four of these pathways, including 
cholesterol transport, hematopoietic cell lineage, 
clathrin/AP2 adaptor complex, and protein folding 
pathways. Our finding that APOE ε4 non-carriers need 
four more steps before AD clinically manifests 
compared to APOE ε4 carriers taps into this 
observation, and could indicate that changes in the 
abovementioned four pathways are indeed necessary to 
acquire before AD manifests clinically. This could 
mean that these pathways are already changed or 
dysregulated at birth in APOE ε4 carriers, indicating 
that these individuals subsequently have a lower 
resilience to the development of dementia. This could in 
turn lead to a lower required number of subsequent 
steps before disease manifestation. Indeed, up to 18% of 
the APOE ε4 carriers in this study developed AD during 
follow-up, yet the lifetime risk of AD among these 
individuals is even higher with almost half of all them 
developing AD in their remaining lifetime. For carriers 
homozygous for APOE ε4 in the high-risk tertile, this 
risk is even higher, and the disease moreover manifests 
earlier, with a 29-year difference in age at onset for AD, 
compared to homozygous APOE carriers at the low-risk 
tertile of the genetic risk score [2]. 
  
The search of finding successful AD therapies is among 
the most challenging and expensive healthcare issue to 
date. So far, many disease-modifying agents aim to 
reduce the production of amyloid-beta (Aβ), or target a 
specific but single part of the disease process [17]. Our 
present study shows that as many as 14 steps are 
required before AD becomes clinically apparent. This 
high number of required steps may signal the need to 
develop multi-domain approaches to target various 
underlying disease-processes simultaneously in order to 
halt or deter neurodegeneration.  
 
Several limitations of this study need to be discussed. 
Firstly, although the use of multistage models produces 
a number as simple, and concrete result, its exact 
biological meaning is complex and remains hard to 
interpret. For instance, multistage models reflect the 
notion and the trajectory of a single cell or cell lineage 
to become malignant in several rate limiting steps in 
cancer research. However, the biological unit and 
meaning of these independent steps is more variable in 
the case of AD, as indeed it is for other 
neurodegenerative diseases such as ALS. This could for 
instance reflect an essential pathophysiological change 
in a single neurovascular unit, but could also relate to a 
key genetic mutation in a single cell or cell lineage. 
Secondly, the underlying multistage model assumes that 
disease development is predominantly genetically 
determined. This means that a certain number of steps, 
all with a similar exposure time, have to occur before 
the specific disease manifests clinically. In most 
instances, this means that the exposure under study 
must be present at birth or during an individual’s early 
life, such as their genes, ethnicity, sex or environmental 
factors present from birth onwards. This leaves little 
room for the incorporation of environmental factors that 
start later in life, such as smoking. While AD has a 
strong genetic component, [2]. the importance of 
lifestyle and environmental factors is also substantial 
[18, 19]. These factors remain however in part 
unaddressed in the current multistage models. Some 
studies in cancer epidemiology have tried to model 
these effects in more complex multistage models, but 
the results of these models turned out to be difficult to 
interpret and are currently poorly validated [10]. Since 
this is the first application of the multistage modelling 
in AD, we relied on a more simple, yet widely used 
multistage model. Future research is encouraged to 
incorporate (time-varying) extensions with environ-
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mental and lifestyle factors. Thirdly, results derived 
from exploratory analyses amongst participants either 
homo- or heterozygous for APOE ε4 should be 
interpreted with caution as these analyses are based on 
relatively small sample sizes. Fourthly, due to various 
reasons including for instance selection bias, the 
presented frequencies of homo- and heterozygous 
carriers for the APOE ε4 allele in this population-based 
cohort study (2.8% homozygous, 25.8% heterozygous), 
may differ from those in the unselected general 
population [20]. Nevertheless, the frequencies in this 
study fell within the reported ranges from several other, 
large population-based cohort studies (Supplementary 
Table 1). Finally, estimates of multistage models are 
vulnerable for several artificial influences on the 
observed incidence patterns, such as community-wide 
disease screening programs or misclassification of 
diagnoses at high ages due to restrained diagnostic 
work-ups [21]. For some diseases, this subsequently 
could influence the estimation of the slope and thus the 
number of steps needed for disease onset. We 
nevertheless minimized these effects by using a cohort 
study with standardized and consistent AD 
ascertainment over time with virtually complete follow-
up (>95% of potential person-years).  
 
In conclusion, we found that AD complies with a 
multistage model characterized by 14 steps that include 
essential facets of biological change which are required 
before AD becomes clinically apparent. Moreover, we 
observed that individuals with a higher genetic 
susceptibility require less of these additional steps 
before disease manifests clinically. Future research is 
warranted to validate the number of steps, to study the 
effects of environmental and lifestyle factors, and to 
further investigate the processes underlying these rate-
limiting steps. These findings could further increase the 
understanding of the pathogenesis of AD, which in turn 
could benefit the development of prevention and 
treatment strategies. 
 
MATERIALS AND METHODS 
 
Study design 
 
This study was embedded within the Rotterdam Study, 
a prospective population-based cohort designed to study 
the occurrence and determinants of age-related diseases 
in the general population. Details regarding the 
objectives and design have been reported previously 
[22]. Briefly, in 1990 inhabitants aged ≥55 years from a 
well-defined suburb in the city of Rotterdam, the 
Netherlands were invited to participate. The initial 
cohort comprised 7,983 individuals. In 2000, 3,011 
individuals who had become 55 years of age or moved 
into the study district since the start of the study if aged 
≥55 years, were added to the cohort. In 2006, a further 
extension of the cohort was initiated in which 3,932 
individuals were included, aged ≥45 years. In total, the 
Rotterdam Study comprises 14,926 individuals aged 
≥45 years. The overall response rate for all three 
recruitment waves was 72%. 
 
This study is registered with the Netherlands National 
Trial Register and WHO International Clinical Trials 
Registry Platform under the shared catalogue number 
NTR6831.  The Rotterdam Study was approved by the 
medical ethics committee of the Erasmus MC University 
Medical Center Rotterdam (registration number MEC 
02.1015) and by the Dutch Ministry of Health, Welfare 
and Sport (Population Screening Act WBO, license 
number 1071272-159521-PG). Written informed consent 
was obtained for all participants. This study is registered 
with the Netherlands National Trial Register and WHO 
International Clinical Trials Registry Platform under the 
shared catalogue number NTR6831. 
 
To model AD as a multistage process, we excluded 
participants with a history of any type of dementia at 
baseline (N=531) and those who were insufficiently 
screened for dementia (N=637). We further excluded 
participants who did not provide informed consent to 
access medical records or hospital discharge letters 
(N=159). Lastly, participants without information on 
their APOE genotype (N=964) or AD-associated genetic 
variants to calculate the genetic risk score (N=1,565) 
were excluded, leaving 11,070 participants for analyses 
(Figure 2).  
 
APOE genotyping and calculation of a weighted 
genetic risk score 
 
DNA was extracted from blood samples drawn by 
venepuncture at baseline. APOE genotype was 
determined using polymerase chain reaction on coded 
DNA samples in the initial cohort and with a bi-allelic 
TaqMan assay (rs7412 and rs429358) in the two 
extensions (RS-II and RS-III). The majority of samples 
(81.1%) were further genotyped with the Illumina 610K 
and 660K chips and imputed to the Haplotype 
Reference Consortium reference panel (version 1.0) 
with Minimac 3. We included 23 genetic variants that 
showed genome wide significant evidence of 
association with AD to calculate a weighted genetic risk 
score (Supplementary Table 2 for an overview of the 
included variants) [9, 23-37]. This score was calculated 
as the sum of the products of single nucleotide 
polymorphism dosages of the 23 genetic variants 
(excluding APOE) and their respective reported effect 
estimates. All 23 variants selected for the calculation of 
the genetic risk score were well imputed (imputation 
score R2 > 0.3, median 0.99). 
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Ascertainment methods of dementia 
 
Baseline and follow-up ascertainment methods for 
dementia have previously been described in detail [19]. 
Participants were screened for dementia at baseline and 
subsequent centre visits with the Mini-Mental State 
Examination and the Geriatric Mental Schedule organic 
level. Those with a Mini-Mental State Examination 
score <26 or Geriatric Mental Schedule score >0 
underwent further investigation and informant 
interview, including the Cambridge Examination for 
Mental Disorders of the Elderly. All participants also 
underwent routine cognitive assessment. In addition, the 
entire cohort was continuously under surveillance for 
dementia through electronic linkage of the study 
database with medical records from general 
practitioners and the regional institute for outpatient 
mental health care. Available information on cognitive 
testing and clinical neuroimaging was used when 
required for diagnosis of dementia subtype. A 
consensus panel led by a consultant neurologist 
established the final diagnosis according to standard 
criteria for AD (NINCDS–ADRDA). Participants were 
censored at date of any type of dementia diagnosis, 
death, loss to follow-up, or 1st January 2016, whichever 
came first. Follow-up was virtually complete (96.3% of 
potential person-years) [38].  
 
The multistage model 
 
Multistage models originate from cancer epidemiology, 
where they were first employed to study the age 
distribution of several cancer types [5, 12, 39, 40]. 
Within this framework it is assumed that cancer 
manifests clinically after a certain threshold number has 
been reached composed of n mutations within one cell. 
This threshold for disease occurrence in that cell has a 
certain probability distribution over time (t), e.g. for an 
 
Figure 2. Flowchart of study population. Abbreviations: AD, Alzheimer’s disease; APOE, Apolipoprotein E. 
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individual the nth mutation occurs at age 50, whereas for 
another individual this nth mutation may occur at age 80. 
Of the required mutations, (n−1) mutations have 
independently taken place at a certain point during the 
lifespan. For each of these mutations, a certain 
probability per time unit (e.g., year) exists that a 
mutation will occur (𝜆𝜆). When a cell is primed, such 
that it has undergone all of these necessary preceding 
mutations, the final mutation (nth mutation) leads to 
clinical manifestation of disease. Subsequently, this 
final nth mutation has to occur after all of these steps and 
can for example not occur in between preceding steps. 
So, the probability density function of time-point t, 
when the nth change takes place is:  
 
𝑓𝑓(𝑡𝑡) ~ 𝜆𝜆1𝜆𝜆2 … 𝜆𝜆𝑛𝑛−1𝜆𝜆𝑛𝑛𝑡𝑡𝑛𝑛−1 
 
It was noted in cancer epidemiology that the age-
specific incidence rate of cancer (‘i’) roughly coincided 
with the probability that at least one cell of all 
independent cells acquired the necessary number of 
seven mutations by that specific age. This means that 
for most types of cancer six preceding rate-limiting 
steps (n−1) are necessary during the lifespan, with a 
seventh and final mutation (nth mutation), leading to 
disease manifestation [41]. It can subsequently be 
shown that if the disease under study fits a multistep 
process, the number of these steps (𝑛𝑛) can be estimated 
with the following formula:  
 log(𝑖𝑖) = (𝑛𝑛 − 1) log(𝑡𝑡) + 𝑐𝑐 
 
in which c is a constant number containing log(𝜆𝜆1𝜆𝜆2 … 𝜆𝜆𝑛𝑛−1𝜆𝜆𝑛𝑛). The common ground of these rate-
limiting definitions is that the speed of a reaction step 
will have a significant effect on the speed of the overall 
chain of events to which the step belongs [42]. A 
reaction step is thus subsequently considered a rate-
limiting step, when the rate of that particular step is 
identical to the overall rate of the entire reaction.  
 
Statistical analysis 
 
We applied a multistage model to determine the slope 
and the number of steps for the development and 
clinical onset of AD. In line with previous studies, the 
incidence rate of AD was calculated per five years age 
categories [5, 9]. Each participant contributed person-
years to specific age categories, until the age at AD 
diagnosis or censoring. To minimize the effects of 
outliers on the slope of the model, we excluded age 
categories with less than 500 person-years or with an 
incidence rate below 1 per 1000 person-years given that 
estimated incidence rates often become instable in the 
extremes of the age distribution [40]. This additional 
criterion resulted in an exclusion of 213,530.6 person-
years, which corresponded to the exclusion of 1,708 of 
the 11,070 participants with age at AD or censoring 
below the first included age category. This left 9,362 
participants available for the final analyses (Figure 2). 
The incidence rate of AD and the five-years age 
categories (log age) were natural log-transformed. 
Linearity was tested based on the adjusted R-squared 
obtained from a linear regression model with log age 
and incidence rate of AD as outcome. Linear models 
were unadjusted.  
 
Additionally, we stratified according to APOE ε4 carrier 
status and on tertiles of a weighted genetic risk score in 
mutually exclusive categories of genetic risk and by 
combining both in order to be able to stratify those 
individuals with the lowest and those with the highest 
AD genetic risk.  
 
Data were handled and analysed with SPSS Statistics 
version 24.0.0.1 (IBM Corp., Armonk, NY) and R, 
CRAN version 3.4.3. 
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SUPPLEMENTARY MATERIAL 
 
 
 
Supplementary Table 1. Frequency of APOE alleles in study population. 
APOE genotype Study population (N=9,362) 
ε2/ε2 63 (0.7) 
ε2/ε3 1,208 (12.9) 
ε2/ε4 250 (2.67) 
ε3/ε3 5,467 (58.4) 
ε3/ε4 2,161 (23.1) 
ε4/ε4 213 (2.8) 
Abbreviations: APOE, apolipoprotein E. 
Data are presented as number (percentage) of participants. 
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Supplementary Table 2. Genetic variants included in the genetic risk score.  
Chr    Rs-id ALT- 
HRC 
Assigned-gene Locus discovered in: Effect estimate Maf Weight 
ALT-HRC 
R2-RS1 R2-RS2 R2-RS3 
  
19       rs4147929 G ABCA7 Hollingworth et al. , Naj et al. Lambert et al. (2013) 0.19 -0.135 0.916       0.917        0.991 
2         rs6733839 T BIN1 Seshadri et al. Lambert et al. (2013) 0.409  0.188 0.960       0.911        0.962 
20       rs7274581 C CASS4 Lambert et al. (2013) Lambert et al. (2013) 0.083 -0.139 0.990       0.989        0.990 
6         rs10948363 G CD2AP Hollingworth et al. , Naj et al. Lambert et al. (2013) 0.266 0.098 0.998       0.998        0.998 
11       rs10838725 C CELF1 Lambert et al. (2013) Lambert et al. (2013)              0.316            0.075                         0.998        0.998       0.998 
8         rs9331896                T                 CLU                        Harold et al. , Lambert et al. (2009)              Lambert et al. (2013)              0.379            0.146                         0.902        0.974       0.901 
1         rs6656401                G                CR1                         Lambert et al. (2009)                                 Lambert et al. (2013)              0.197           -0.157                        0.953      0.948         0.950 
10       rs7920721                G                ECHDC3                 Desikan et al.                                                Desikan et al.                           0.387           -0.067                       1.000       1.000        1.000 
7         rs11771145              A                EPHA1                    Hollingworth et al. , Naj et al.                     Lambert et al. (2013)              0.338           -0.102                      0.998        0.998       0.999 
14       rs17125944              C                 FERMT2                 Lambert et al. (2013)  Lambert et al. (2013)  0.092  0.122  1.000       1.000    1.000 
6         rs111418223 A HLA-DRB1/5 Lambert et al. (2013) Lambert et al. (2013) 0.276 -0.108 0.314       0.312        0.314 
4         rs13113697 G HS3ST1 Desikan et al. Desikan et al. 0.283 -0.067 0.999       0.998        0.999 
2         rs35349669 T INPP5D Lambert et al. Lambert et al. (2013) 0.488 0.066 0.975       0.973        0.976 
17       rs118172952 G KANSL1 Jun et al. Lambert et al. (2013) 0.873 -0.151 0.710       0.700     0.708 
5         rs190982 A MEF2C Lambert et al. (2013) Lambert et al. (2013) 0.408 0.080 0.979       0.934        0.978 
11       rs983392 G MS4A6A Hollingworth et al. , Naj et al. Lambert et al. (2013) 0.403 -0.108 0.989        0.990       0.991 
7         rs2718058 G NME8 Lambert et al. (2013) Lambert et al. (2013) 0.373 -0.070 1.000          1.000     1.000 
11 rs10792832 G PICALM Harold et al. Lambert et al. (2013) 0.358 0.130 0.999 0.999     0.999 
8 rs28834970 C PTK2B Lambert et al. (2013) Lambert et al. (2013) 0.366 0.096 0.993 0.990     0.994 
14 rs10498633 T SLC24A4-RIN3 Lambert et al. (2013) Lambert et al. (2013) 0.217 -0.104 0.999 0.999     1.000 
11       rs11218343 C SORL1 Lambert et al. (2013) Lambert et al. (2013) 0.039 -0.270 0.998        0.995       0.998 
6         rs75932628 T TREM2 Guerreiro et al. , Jonsson et al. Ruiz et al. 0.0016         0.889 0.762        0.726       0.668 
7         rs1476679 T ZCWPW1 Lambert et al. (2013) Lambert et al. (2013) 0.287 0.078 0.995         0.996     0.995 
Ordered by assigned gene name. References: Harold et al.[1], Seshadri et al.[2], Hollingworth et al.[3], Naj et al.[4], Lambert et al. (2009,2013)[5, 6], Jonsson et 
al.[7],  and Ruiz et al.[8] Minor allele Frequency (Maf) of Rotterdam Study (RS) 1 is shown and is representative of the MAF in RS2 and RS3. R2= imputation 
quality. RS1= initial Rotterdam Study cohort, RS2=first extension Rotterdam Study, RS3=second extension. Rotterdam Study cohorts were imputed separately. 
Gene names are ncbi gene names assigned to the loci in the corresponding references. 
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